Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
Eiji Harada,1 Osamu Shirakawa,2 Yoichi Satoi,3 Lauren B Marangell,4 Rodrigo Escobar5 1Eli Lilly Japan K.K., Medicines Development Unit Japan, Medical Science, Kobe, 2Department of Neuropsychiatry, Kinki University Faculty of Medicine, Osakasayama, 3Eli Lilly Japan K.K., Medicines Development Unit J...
Saved in:
| Main Authors: | Harada E, Shirakawa O, Satoi Y, Marangell L, Escobar R |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-01-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/treatment-discontinuation-and-tolerability-as-a-function-of-dose-and-t-peer-reviewed-fulltext-article-NDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
by: Novick D, et al.
Published: (2016-02-01) -
Treatment of Fibromyalgia - duloxetine or pregabalin?
by: Magdalena Bujak, et al.
Published: (2025-04-01) -
Efficacy of Duloxetine for Postspine Surgery Pain: A Systematic Review and Meta‐Analysis
by: Abdulsalam Mohammed Aleid, et al.
Published: (2025-01-01) -
Comparing the effectiveness of pregabalin and duloxetine in the management of neuropathic pain
by: Rojgar Hamed Ali, et al.
Published: (2025-04-01) -
A comparative study of the effectiveness and safety of pregabalin and duloxetine in the treatment of chemotherapy-induced neuropathic pain
by: Yogendra Singhal, et al.
Published: (2025-01-01)